Literature DB >> 12118337

Involvement of reactive oxygen species in aclarubicin-induced differentiation and invasiveness of HL-60 leukemia cells.

Doriane Richard1, Patrick Hollender, Benoît Chénais.   

Abstract

Aclarubicin (ACLA), which belongs to the anthracycline class of antineoplastic agents, has been demonstrated as a differentiating agent of human leukemia, including HL-60 cells. We report here on the incidence of ACLA-induced differentiation on matrix metalloproteinase (MMP) expression and cell invasiveness. The aim of this study was to investigate the involvement of reactive oxygen species (ROS) as mediators of ACLA-induced effects. By using a fluorescent probe, we showed that subtoxic (i.e. differentiating) concentration of ACLA generate reactive oxygen species in HL-60 cells. ACLA-differentiated cells exhibited an increased proMMP-9 secretion which has been observed by gelatin zymography and immunoassay. Antioxidants were able to inhibit ACLA-induced differentiation and proMMP-9 secretion. Furthermore, RT-PCR showed that ACLA increased MMP-9 and tissue inhibitor of MMP (TIMP-1) expression in a ROS-dependent manner. In addition, the migration and invasion capacities of HL-60 cells were enhanced by ACLA treatment, but only partially reversed by antioxidants. Altogether, these results evidenced ROS as messengers of ACLA-induced differentiation and MMP-9 expression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12118337

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  2 in total

1.  8-Bromo-7-methoxychrysin-induced apoptosis of hepatocellular carcinoma cells involves ROS and JNK.

Authors:  Xiao-Hong Yang; Xing Zheng; Jian-Guo Cao; Hong-Lin Xiang; Fei Liu; Yuan Lv
Journal:  World J Gastroenterol       Date:  2010-07-21       Impact factor: 5.742

Review 2.  Spinal muscular atrophy.

Authors:  Susan T Iannaccone; Stephen A Smith; Louise R Simard
Journal:  Curr Neurol Neurosci Rep       Date:  2004-01       Impact factor: 5.081

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.